Revenues down for Moderna, up for Regeneron in Q1

Moderna and Regeneron released their latest respective earnings reports and business updates Thursday morning.

For Moderna, the start to 2023 was challenging for its topline, with revenues declining from $6.1 billion in Q1 2022 to $1.9 billion. Similarly, Moderna’s net income dropped from $3.7 billion to a mere $79 million while the company’s diluted earnings per share (EPS) fell from $8.58 to $0.19.